Administration of a new diabetes-specific enteral formula results in an improved 24 h glucose profile in type 2 diabetic patients

Antonio Ceriello, Mirian Lansink, Carlette H F C Rouws, Katrien M J van Laere, Gary S. Frost

Research output: Contribution to journalArticlepeer-review


Aims: Study the effect of several boluses of a new diabetes-specific formula (DSF) during the day on 24 h glucose profile. Methods: In this randomized, controlled, double-blind, cross-over study 12 ambulatory type 2 diabetic patients were included. Subjects received a new DSF and an isocaloric standard fibre-containing formula (SF) while continuing their anti-diabetic medication. Subjects received 100% of their calculated daily energy requirements as bolus feeding every 3 h (5 times/day, starting at 8.00 a.m. ± 1 h). Results: Glucose profiles were significantly better after administration of DSF compared with SF determined as mean glucose concentration (±SEM) (8.7 ± 0.5 versus 9.6 ± 0.6 mmol/L, p <0.05 during 24 h; 9.4 ± 0.6 versus 10.7 ± 0.6 mmol/L, p <0.001 during daytime) or as incremental area under the curve during daytime (-44%; p <0.05). Subjects receiving DSF experienced less hyperglycaemic time over 24 h (-26%; p <0.05) and during daytime (-30%; p <0.05). Furthermore, lower individual and mean (delta) peak glucose levels were found (p <0.05). No clinically relevant differences in gastrointestinal tolerance were observed. Conclusions: Using DSF resulted in significantly better 24 h and postprandial glucose profiles than fibre-containing SF after bolus administration and may therefore help to improve glycaemic control in diabetic patients.

Original languageEnglish
Pages (from-to)259-266
Number of pages8
JournalDiabetes Research and Clinical Practice
Issue number3
Publication statusPublished - Jun 2009


  • 24 h glucose profile
  • Diabetes mellitus
  • Enteral nutrition
  • Postprandial glucose

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology


Dive into the research topics of 'Administration of a new diabetes-specific enteral formula results in an improved 24 h glucose profile in type 2 diabetic patients'. Together they form a unique fingerprint.

Cite this